CNTX RSI Chart
Last 7 days
7.0%
Last 30 days
43.9%
Last 90 days
92.3%
Trailing 12 Months
257.1%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 21, 2023 | lehr martin a. | bought | 4,900 | 0.8415 | 5,823 | chief executive officer |
Feb 13, 2023 | lehr martin a. | bought | 4,900 | 0.8742 | 5,606 | chief executive officer |
Feb 06, 2023 | lehr martin a. | bought | 4,900 | 0.9723 | 5,040 | chief executive officer |
Jan 30, 2023 | lehr martin a. | bought | 4,900 | 0.6974 | 7,027 | chief executive officer |
Jan 23, 2023 | lehr martin a. | bought | 4,900 | 0.7166 | 6,839 | chief executive officer |
Jan 17, 2023 | lehr martin a. | bought | 4,995 | 0.7364 | 6,783 | chief executive officer |
Dec 16, 2022 | lehr martin a. | bought | 14,796 | 0.7398 | 20,000 | chief executive officer |
Dec 16, 2022 | minai-azary jennifer lynn | bought | 18,500 | 0.74 | 25,000 | chief financial officer |
Dec 09, 2022 | levit alex c. | bought | 5,094 | 0.8491 | 6,000 | chief legal officer, corp. sec |
Aug 19, 2022 | lehr martin a. | bought | 24,064 | 1.8511 | 13,000 | chief executive officer |
Which funds bought or sold CNTX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | STATE STREET CORP | unchanged | - | 8,227 | 45,412 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | sold off | -100 | -123 | - | -% |
May 15, 2024 | Federation des caisses Desjardins du Quebec | new | - | 1,104 | 1,104 | -% |
May 15, 2024 | ADAR1 Capital Management, LLC | new | - | 284,189 | 284,189 | 0.06% |
May 15, 2024 | Ally Bridge Group (NY) LLC | unchanged | - | 181,487 | 1,001,810 | 0.56% |
May 15, 2024 | Opaleye Management Inc. | added | 13.68 | 427,783 | 1,529,530 | 0.35% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -4.48 | 1,253 | 8,773 | -% |
May 15, 2024 | OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | unchanged | - | 74,169 | 409,412 | 0.03% |
May 15, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | unchanged | - | 26,452 | 146,016 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | reduced | -5.28 | 2,813 | 20,757 | -% |
Unveiling Context Therapeutics Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Context Therapeutics Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Context Therapeutics Inc. News
Balance Sheet | ||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2019Q4 |
Assets | -31.2% | 11.00 | 16.00 | 23.00 | 28.00 | 32.00 | 38.00 | 42.00 | 45.00 | 47.00 | 51.00 | 2.00 | 2.00 | 1.00 | 1.00 | 0.00 |
Current Assets | -31.2% | 11.00 | 16.00 | 23.00 | 28.00 | 32.00 | 38.00 | 42.00 | 44.00 | 47.00 | 51.00 | 0.00 | - | - | 0.00 | 0.00 |
Cash Equivalents | -29.9% | 10.00 | 14.00 | 22.00 | 25.00 | 30.00 | 35.00 | 39.00 | 43.00 | 46.00 | 50.00 | 0.00 | 1.00 | 2.00 | 0.00 | 0.00 |
Net PPE | -16.5% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - |
Liabilities | -37.8% | 3.00 | 4.00 | 5.00 | 4.00 | 3.00 | 3.00 | 4.00 | 3.00 | 2.00 | 3.00 | 4.00 | 6.00 | 8.00 | 10.00 | 24.00 |
Current Liabilities | -37.8% | 3.00 | 4.00 | 5.00 | 4.00 | 3.00 | 3.00 | 4.00 | 3.00 | 2.00 | 3.00 | 4.00 | - | - | 10.00 | 24.00 |
LT Debt, Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.00 | 21.00 |
Shareholder's Equity | -28.9% | 8.00 | 12.00 | 18.00 | 24.00 | 29.00 | 35.00 | 38.00 | 42.00 | 45.00 | 48.00 | - | - | - | - | - |
Retained Earnings | -5.4% | -71.72 | -68.05 | -61.28 | -55.40 | -50.40 | -44.09 | -40.53 | -36.70 | -32.69 | -29.25 | -26.20 | - | - | -18.80 | -25.44 |
Additional Paid-In Capital | 0.3% | 80.00 | 80.00 | 80.00 | 79.00 | 79.00 | 79.00 | 79.00 | 78.00 | 78.00 | 78.00 | 3.00 | - | - | 2.00 | 1.00 |
Shares Outstanding | 0% | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 | - | 0.00 | 0.00 | 0.00 | 0.00 |
Float | - | - | - | - | 24.00 | - | - | - | 32.00 | - | - | - | - | - | - | - |
Cashflow (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2019Q4 |
Cashflow From Operations | 39.7% | -4,360 | -7,227 | -3,460 | -4,631 | -5,728 | -3,929 | -2,994 | -2,805 | -3,820 | -4,961 | -43.63 | -2,078 | -1,715 | - | - | - |
Share Based Compensation | -6.3% | 240 | 256 | 255 | 283 | 283 | 244 | 277 | 241 | 215 | 204 | 162 | 119 | 26.00 | - | - | - |
Cashflow From Investing | - | - | - | - | - | - | - | -500 | -1.84 | -35.00 | - | - | -250 | - | - | - | - |
Cashflow From Financing | - | - | - | - | - | - | - | - | - | -102 | 54,228 | -816 | 1,948 | 3,035 | - | - | - |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 1,973,209 | $ 4,534,676 |
General and administrative | 1,850,292 | 2,131,872 |
Loss from operations | (3,823,501) | (6,666,548) |
Interest income | 152,351 | 355,542 |
Other income | 3,353 | 2,688 |
Net loss | $ (3,667,797) | $ (6,308,318) |
Net income (loss) per share - basic (in dollars per share) | $ (0.23) | $ (0.40) |
Net income (loss) per share - diluted (in dollars per share) | $ (0.23) | $ (0.40) |
Weighted average common shares outstanding - basic (in shares) | 15,966,053 | 15,966,053 |
Weighted average common shares outstanding - diluted (in shares) | 15,966,053 | 15,966,053 |
Condensed Consolidated Balance Sheets - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 10,089,207 | $ 14,449,827 |
Prepaid expenses and other current assets | 949,489 | 1,597,384 |
Total current assets | 11,038,696 | 16,047,211 |
Property and equipment, net | 12,956 | 15,524 |
Total assets | 11,051,652 | 16,062,735 |
Current liabilities: | ||
Accounts payable | 2,045,364 | 2,383,016 |
Accrued expenses and other current liabilities | 563,058 | 1,808,699 |
Total current liabilities | 2,608,422 | 4,191,715 |
Total liabilities | 2,608,422 | 4,191,715 |
Commitments and Contingencies | ||
Stockholders' equity: | ||
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding | 0 | 0 |
Common stock, $0.001 par value; 100,000,000 shares authorized; 15,966,053 shares issued and outstanding at March 31, 2024 and December 31, 2023 | 15,966 | 15,966 |
Additional paid-in capital | 80,149,651 | 79,909,644 |
Accumulated deficit | (71,722,387) | (68,054,590) |
Total stockholders' equity | 8,443,230 | 11,871,020 |
Total liabilities and stockholders' equity | $ 11,051,652 | $ 16,062,735 |